Pain Medicine
The Future of Pain Medicine

The Pain Treatment Pipeline

After decades with few genuinely new options, pain treatment is moving again. This tracker follows the notable drugs and devices in development — what each one is, how it works, and how far along it is — from suzetrigine, the first non-opioid painkiller of a new class in decades, to gene therapies just entering human trials. It is reporting on the science, updated as it moves; it is not medical advice.

Written from primary sources. Built from the cited references below — independent medical review is pending. Educational information, not medical advice.

Last updated August 26, 2026

The pain-treatment pipeline boardA swimlane chart. Rows are mechanism types — small molecule, biologic, device, gene therapy. Columns run Phase 1, Phase 2, Phase 3, then Approved, separated by a dashed line marking FDA approval. Each candidate is a dot in its lane and stage; halted candidates appear in a separate siding at the bottom.closer to patients →Small moleculeBiologicDeviceGene therapyPhase 1(1)Phase 2(3)Phase 3(2)Approved(2)FDA approvalPilavapadinVX-993CebranopadolResiniferatoxinSuzetrigineLEVI-04Evoke SCSST-503HaltedTanezumab— biologic
The board, drawn live from the tracker data: each lane is a mechanism type, each column a development stage, and the dashed teal line is FDA approval. Halted candidates drop to the siding at the bottom — tanezumab fell at the line.

For most of the last forty years, treating pain meant choosing among old drug classes — opioids, anti-inflammatories, a handful of nerve-pain medicines borrowed from other fields. That has started to change. Below is what is actually moving through development now: what each candidate is, how it works, and how far along it is.

A word on how to read it, because this is a page where honesty matters more than hype. A candidate in a trial is not an available treatment, and most investigational drugs never reach patients at all. Only the entries marked Approved are cleared for use — and even then only for the specific condition on their label. This is reporting on the science, not medical advice; decisions belong with your clinician.

And because much of this pipeline exists to reduce reliance on opioids: if you or someone you love is struggling with opioid or other substance use, the SAMHSA National Helpline is free, confidential, and open 24/7 at 1-800-662-HELP (4357).

Approved & available2

  • Suzetrigine

    VX-548 · Journavx

    Approved
    Mechanism
    Selective NaV1.8 sodium-channel blocker
    Type
    Small molecule
    For
    Moderate-to-severe acute pain
    Sponsor
    Vertex Pharmaceuticals

    The first non-opioid painkiller of a genuinely new class in decades — it blocks pain signals in the peripheral nerves rather than acting on the brain, so it carries no opioid addiction risk.

    FDA-approved for acute pain (Jan 2025). Phase 3 trials in diabetic nerve pain and lumbosacral radiculopathy are ongoing — those chronic-pain uses are not yet approved.

    Vertex — FDA approval of Journavx· status checked 2026-08

  • Evoke closed-loop SCS

    ECAP-controlled SCS

    Approved
    Mechanism
    Closed-loop spinal cord stimulation that reads the cord's response (ECAPs) and self-adjusts
    Type
    Device
    For
    Chronic intractable trunk & limb pain
    Sponsor
    Saluda Medical

    The first stimulator that measures the spinal cord's actual response to each pulse and corrects itself more than 100 times a second — in trials it outperformed conventional open-loop stimulation.

    FDA-approved 2022. Represents the shift from fixed-output devices toward feedback-controlled neuromodulation.

    Saluda Medical — FDA approval of Evoke· status checked 2026-08

In Phase 3 (pivotal trials)2

  • Cebranopadol

    Phase 3
    Mechanism
    Dual NOP + µ-opioid receptor agonist
    Type
    Small molecule
    For
    Moderate-to-severe acute pain
    Sponsor
    Tris Pharma

    Aims to keep opioid-level pain relief while lowering abuse potential — in human abuse-potential studies it was reported less abusable than oxycodone and tramadol.

    Positive topline results from two Phase 3 trials (ALLEVIATE-1 and -2). It still engages the µ-opioid receptor, so it is opioid-adjacent, not opioid-free; not yet FDA-filed or approved.

    Tris Pharma — ALLEVIATE-2 Phase 3 results· status checked 2026-03

  • Resiniferatoxin

    RTX

    Phase 3
    Mechanism
    Ultra-potent TRPV1 agonist that quiets pain-sensing nerve endings
    Type
    Small molecule
    For
    Knee osteoarthritis pain
    Sponsor
    Grünenthal

    A single injection into the joint 'defunctionalizes' the local pain nerves for long-lasting, non-opioid relief. It holds FDA Breakthrough Therapy designation.

    In a global Phase 3 program of more than 1,800 patients.

    ClinicalTrials.gov — RTX knee OA Phase 3 (NCT04044742)· status checked 2026-08

In Phase 23

  • Pilavapadin

    LX9211

    Phase 2
    Mechanism
    AAK1 (adaptor-associated kinase 1) inhibitor
    Type
    Small molecule
    For
    Diabetic peripheral neuropathic pain
    Sponsor
    Lexicon Pharmaceuticals

    A once-daily pill hitting a brand-new, non-opioid target for nerve pain. Its Phase 2b study met its goals at the 10 mg dose, which is moving toward Phase 3.

    Holds FDA Fast Track designation; Phase 3 planned.

    Lexicon — PROGRESS Phase 2b topline results· status checked 2025-03

  • LEVI-04

    Phase 2
    Mechanism
    Neurotrophin-3 (NT-3) inhibitor (p75 receptor fusion protein)
    Type
    Biologic
    For
    Knee osteoarthritis pain
    Sponsor
    Levicept

    Targets the same neurotrophin pain pathway as earlier anti-NGF drugs but appears to spare the joint — its Phase 2 trial improved pain and function without the joint-damage signal that sank tanezumab.

    Phase 2 results published in The Lancet (2026); Phase 3 in planning.

    The Lancet — LEVI-04 Phase 2 trial· status checked 2026-03

  • VX-993

    Phase 2
    Mechanism
    Next-generation selective NaV1.8 sodium-channel blocker
    Type
    Small molecule
    For
    Diabetic neuropathy (acute-pain arm halted)
    Sponsor
    Vertex Pharmaceuticals

    A reminder that even a hot new class stumbles: its acute-pain Phase 2 missed the primary endpoint in 2025, so Vertex dropped that use — but the chronic nerve-pain program continues.

    Not advancing as an acute-pain monotherapy; Phase 2 continues in diabetic peripheral neuropathy.

    Vertex — VX-993 Phase 2 acute-pain results· status checked 2025-08

In Phase 1 (first-in-human)1

  • ST-503

    Phase 1
    Mechanism
    Zinc-finger repressor that epigenetically dials down the SCN9A / NaV1.7 pain gene
    Type
    Gene therapy
    For
    Idiopathic small fiber neuropathy
    Sponsor
    Sangamo Therapeutics

    The frontier's edge: a one-time gene therapy that turns down the body's master pain gene at its source in the sensory nerves, aiming for durable relief. First-in-human.

    Entering a Phase 1 trial (NCT06980948) after primate data published in 2026; earliest-stage and unproven in people.

    ClinicalTrials.gov — ST-503 Phase 1 (NCT06980948)· status checked 2026-03

Halted1

  • Tanezumab

    Discontinued
    Mechanism
    Anti-NGF (nerve growth factor) monoclonal antibody
    Type
    Biologic
    For
    Osteoarthritis & chronic low back pain
    Sponsor
    Pfizer / Eli Lilly

    The cautionary tale of the field: it clearly relieved pain, but an FDA advisory panel voted 19–1 against it over a risk of rapidly progressive joint destruction. Development was halted in 2021.

    Discontinued. Its failure reframed the whole anti-NGF class — and is the backdrop against which newer neurotrophin drugs like LEVI-04 are measured.

    FierceBiotech — Lilly & Pfizer halt tanezumab· status checked 2021-12

How this tracker is maintained

Every entry is dated and linked to a primary source — a regulator, a trial registry, a peer-reviewed journal, or the sponsor’s own release. Development is fast-moving, so this page is re-checked quarterly; the status shown was last reviewed on August 26, 2026. For anything you plan to act on, confirm the current status on ClinicalTrials.gov and with your care team.

This tracker covers 9 notable candidates and is not exhaustive — the full pain pipeline runs to hundreds of programs. It favors candidates that are late-stage, first-in-class, or otherwise signal where the field is heading.

Frequently asked questions

Does a drug being 'in the pipeline' mean I can get it?
Usually no. Most entries here are still in clinical trials and are not available as prescription treatments — and most investigational drugs never reach the market at all. Only entries marked 'Approved' are cleared for use, and even then only for the specific condition on their label. Ask your clinician what is actually available for your situation.
What do the trial phases mean?
Phase 1 tests safety in a small group. Phase 2 looks for early signs the treatment works and refines the dose. Phase 3 is the large, pivotal test against placebo or standard care that regulators weigh for approval. 'Approved' means the FDA has cleared it. Each phase is a filter — many candidates stop here.
Why include treatments that failed?
Because an honest pipeline includes its setbacks. Failures like tanezumab and the halted acute-pain arm of VX-993 shaped the field and explain why today's candidates are designed the way they are. Showing only the wins would misrepresent how slow and uncertain drug development really is.

References

  1. 1.FDA guidance — Development of Non-Opioid Analgesics for Chronic Pain — U.S. FDA
  2. 2.ClinicalTrials.gov — registry of clinical studies — NIH
  3. 3.FDA Approves Non-Opioid Treatment for Moderate-to-Severe Acute Pain — IASP

Keep reading

The future of pain medicineHow the whole field is changing — the hub this tracker sits in.The three types of painWhy new drugs target specific pain mechanisms.

This page is educational and is not a substitute for professional medical advice. Talk with a qualified clinician about your own situation. Pain Medicine does not provide treatment or dosing guidance.